Good morning, HealthTech insiders. Radiology Partners has already used AI to draft nearly 8 million imaging reports. On Wednesday, its technology subsidiary published findings from a 237,905-exam study showing that its investigational AI helped identify roughly 40% more findings, while experienced radiologists read scans up to 31% faster. The technology goes beyond flagging abnormalities. It writes the entire report for a radiologist to review.

And that is only one of three major developments in today's Signal. Neuralink is expanding its brain implant research into chronic stroke, while Guardant Health has added five epigenomic applications to help predict cancer treatment response from a blood draw. Different technologies, but the same shift underneath them: machines are moving beyond detecting signals to interpreting what those signals mean for clinical decisions. The next challenge is proving those interpretations are reliable enough to act on.

In today's Signal:

You've spent years close to a broken industry or process. You know exactly what would fix it. But you’ve never had the time or resources to make it happen.

With Lovable, your expertise is all you need. Describe the solution to your problem — a website, a dashboard, an internal tool — and get professional-grade software back. You make every call on how it works, because you're the one who knows what it needs to do.

Start today and take $5 off your first month.

Build the fix, $5 off

_{^{Discount of $5 applies to first month of any paid plan. You need to sign up via this webpage in order to claim the discount. The discount applies to new and returning users without an active paid plan. Terms apply.}}

On November 11, Mosaic Clinical Technologies, a subsidiary of Radiology Partners, reported results from an ongoing internal study of investigational vision-language models developed by its Cognita Imaging AI lab. Across 50 conditions on CT and X-ray, AI-generated draft reports surfaced additional findings confirmed by blinded expert radiologists, improving detection by roughly 40% on average and up to 110% for certain findings.

The details:

The Signal: Most radiology AI flags individual findings. Mosaic's models draft entire reports, shifting radiologists from authors to editors. Radiology Partners controls the technology, clinical workflow and imaging volume needed to test that approach at scale. But the results are company-run and not yet peer reviewed. The bigger test is whether detecting more findings improves patient outcomes without triggering unnecessary follow-up imaging.

On November 10, Neuralink registered PRIME2 (NCT07929792), an early feasibility study of its N1 brain-computer interface implanted by the R1 surgical robot. For the first time in a U.S. Neuralink registry entry, adults with chronic ischemic stroke and one-sided arm weakness are eligible, alongside people with spinal cord injury or ALS.

The details:

The Signal: Chronic stroke could open a much larger market for brain-computer interfaces, but the commercial challenge is tougher. Unlike many patients with severe paralysis, stroke survivors may retain alternative ways to interact with technology. Neuralink must demonstrate meaningful improvements in daily independence, not just cursor accuracy. That distinction will shape clinical adoption and reimbursement.

On November 11, Guardant Health introduced five epigenomic applications for Guardant360 Liquid, powered by its InfinityAI platform. The technology analyzes methylation patterns in circulating tumor DNA to predict treatment response, extending liquid biopsy beyond identifying actionable mutations.

The details:

The Signal: Liquid biopsy has largely focused on identifying mutations. Methylation adds information about tumor biology and potential treatment response, increasing the value of an existing blood draw. For Guardant, that creates new clinical and commercial opportunities without requiring a separate test. But prospective validation and payer acceptance remain essential before these scores routinely influence treatment selection.

The deals:

The pattern: Investors are backing technologies that turn raw clinical data into structured, actionable decisions. Whether the input is a medical chart, hospital room, sleep record or blood sample, the value lies in interpretation that can be trusted, audited and integrated into care.

1. The Draft Comes First: Radiology Partners, Vision-Language Models and the New Economics of the Read

Inside the 237,905-exam study, the economics of AI-generated radiology reports, the regulatory path and what changes when radiologists become editors rather than authors.

2. Beyond Paralysis: What Neuralink's Stroke Arm Says About the Brain-Computer Interface Market

Why chronic stroke changes the commercial opportunity, how competing BCI approaches compare and what early feasibility evidence must establish before reimbursement becomes realistic.

3. One Tube, More Answers: Guardant's Methylation Bet and the Next Phase of Liquid Biopsy

How methylation expands liquid biopsy beyond mutations, what current evidence supports, the competitive landscape and the reimbursement challenge for additional applications.

Nearly 8 million AI-drafted imaging reports. A brain implant study expanding into stroke. Five new cancer treatment predictors extracted from an existing blood test.

The common thread is interpretation. Healthcare companies are finding new value in data they already collect, moving AI closer to clinical decisions rather than simply helping clinicians find information.

But there is a catch. Much of today's evidence still comes from the companies developing the technology. Independent validation, clinical outcomes and reimbursement will determine which advances move from promising demonstrations into routine care.

The next competitive advantage may not be collecting more data. It may be proving that the interpretation is worth trusting.

See you tomorrow,

Dr. Dereck Mush, MD, MBA

The HealthTech Signal is independently funded. Sponsorships help us invest in better reporting, research, and a stronger newsletter for our readers. Want to reach HealthTech founders & executives while supporting the Signal? Get in touch.

Was this email forwarded to you? Sign up here.